title: Riociguat: PATENT-1 Study.
abstract: Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1) study.
authors.affiliation: Aswan Heart Centre, Aswan, Egypt, Aswan, Egypt.
authors.forename: Karim
authors.initials: K
authors.lastname: Said